Please use this identifier to cite or link to this item: http://hdl.handle.net/20.500.12779/5103
DC FieldValueLanguage
dc.contributor.authorCappelli, Andreaen_us
dc.contributor.authorG., PERICOT MOHRen_us
dc.contributor.authorGiuliani, Germanoen_us
dc.contributor.authorS., Galeazzien_us
dc.contributor.authorAnzini, Maurizioen_us
dc.contributor.authorL., Mennunien_us
dc.contributor.authorF., Ferrarien_us
dc.contributor.authorF., Makovecen_us
dc.contributor.authorE. M., Kleinrathen_us
dc.contributor.authorT., Langeren_us
dc.contributor.authorValoti, Massimoen_us
dc.contributor.authorGiorgi, Gianlucaen_us
dc.contributor.authorVomero, Salvatoreen_us
dc.date.accessioned2021-03-30T15:49:03Z-
dc.date.available2021-03-30T15:49:03Z-
dc.date.issued2006-
dc.identifier.issn0022-2623en_US
dc.identifier.urihttp://hdl.handle.net/20.500.12779/5103-
dc.description35114en_US
dc.language.isoenen_US
dc.relationNoneen_US
dc.relation.ispartofJOURNAL OF MEDICINAL CHEMISTRYen_US
dc.titleFurther studies on imidazo[4,5-b]pyridine AT1 angiotensin II receptor antagonists. Effects of the transformation of the 4-phenylquinoline backbone into 4-phenylisoquinolinone or 1-phenylindene scaffolds.en_US
dc.typeArticleen_US
dc.identifier.doi10.1021/jm0603163en_US
dc.identifier.scopus2-s2.0-33750488442en_US
dc.identifier.isiWOS:000241553700005en_US
dc.relation.volume49en_US
dc.description.firstpage6451en_US
dc.description.lastpage6464en_US
dc.description.thirdmissionNot applicableen_US
item.cerifentitytypePublications-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.openairetypeArticle-
item.fulltextNo Fulltext-
crisitem.author.orcid0000-0003-4140-3028-
crisitem.author.orcid0000-0001-8111-3776-
crisitem.author.orcid0000-0002-7481-5566-
crisitem.author.orcid0000-0002-8817-7745-
Appears in Collections:Publications
Show simple item record

Page view(s)

505
Last Week
0
Last month
343
checked on Jun 18, 2021

Google ScholarTM

Check

Altmetric


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.